Showing 4011-4020 of 5646 results for "".
- Aflibercept 8 mg BLA for Treatment of Wet AMD and DME Accepted for FDA Priority Reviewhttps://modernod.com/news/aflibercept-8-mg-bla-for-treatment-of-wet-amd-and-dme-accepted-for-fda-priority-review/2481433/Regeneron Pharmaceuticals announced that the FDA has accepted for priority review the Biologics License Application (BLA) for aflibercept 8 mg for treatment of patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy. The FDA t
- CDC Expands Recall of OTC Artificial Tearshttps://modernod.com/news/cdc-expands-recall-of-otc-artificial-tears/2481430/After reports of additional infections, the Centers for Disease Control and Prevention (CDC) has expanded its recall of OTC eye drops to include Delsam Pharma’s Artificial Tears products. The call for immediate discontinuation comes a month after the agency recommended immediate discontinua
- EyeCheq adds Jai G. Parekh, MD, to its Executive Teamhttps://modernod.com/news/eyecheq-adds-jai-g-parekh-md-mba-to-its-executive-team/2481428/EyeCheq, the developer of a fully autonomous eye screening platform using artificial intelligence (AI), announced that Jai G. Parekh, MD, FAAO, has been named Executive Vice-President and Chief Innovation Officer. Dr. Parekh, a dual-train
- Spectrum Ophthalmics Launches New Range of Dry Eye Productshttps://modernod.com/news/spectrum-ophthalmics-launches-new-range-of-dry-eye-products/2481427/Spectrum Ophthalmics has launched a new range of dry eye products in the UK. The products include the OptiClear IPL for the treatment of dry eye disease (DED), and a 3nethra classic HD fundus camera for the diagnosis of DED. The OptiClear IPL uses light energy to rejuvenate Me
- Envision University Sets Agenda for In-Person Spring 2023 Conferencehttps://modernod.com/news/envision-university-sets-agenda-for-in-person-spring-2023-conference/2481426/The agenda has been set for the Envision Conference West, which will be held in collaboration with UT Health Department of Occupational Therapy, March 30-April 1, 2023, at the Academic Learning and Teaching Center of UT Health in San Antonio, Texas. The Envision Conference is the only multid
- Clearside Biomedical Announces Positive Data on CLS-AX OASIS Clinical Trial and Use of SCS Microinjectorhttps://modernod.com/news/clearside-biomedical-announces-positive-data-on-cls-ax-oasis-clinical-trial-and-use-of-scs-microinjector/2481423/Clearside Biomedical announced data from presentations delivered at the Angiogenesis, Exudation, and Degeneration 2023 meeting and The Macula Society 46th Annual Meeting. “The promising durability data from our OASIS clinical trial continues to garner si
- Vision Expo East Announces Keynote Speakerhttps://modernod.com/news/vision-expo-east-announces-keynote-speaker/2481419/Vision Expo East announced that Jason Romero, a legally blind ultra-runner, will be the keynote speaker at the annual conference in New York City from March 16-19, 2023 (Education opens March 16; Exhibits open March 17). “After losing his vision to a dege
- Brent Saunders Returns to Bausch + Lomb as CEO and Chair of the Board of Directorshttps://modernod.com/news/brent-saunders-returns-to-bausch-lomb-to-serve-as-ceo-and-chair-of-the-board-of-directors/2481411/After nearly a decade, pharma executive Brent Saunders is returning to Bausch + Lomb where he will serve as CEO and Chair of the Board of Directors, effective March 6, 2023. Mr. Saunders served as Bausch + Lomb's CEO from 2010 to 2013 before its sale to Valeant Pharmaceuti
- Harrow Launches Next-Generation Compounded Atropine Formulationshttps://modernod.com/news/harrow-launches-next-generation-compounded-atropine-formulations/2481410/Harrow announced the launch of its patent-pending, next-generation compounded atropine formulations. The formulations are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx. According to Harrow, the ImprimisRx
- Ocular Therapeutix Announces Interim Data from the Ongoing US Phase 1 Trial Evaluating OTX-TKI for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-interim-data-from-the-ongoing-us-phase-1-trial-evaluating-otx-tki-for-the-treatment-of-wet-amd/2481406/Ocular Therapeutix announced interim 10-month data from its US phase 1 clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseas